BioLayer

DECENTRALIZED BIOLOGICAL INTELLIGENCE INFRASTRUCTURE

[BioLayer @BioLayer_]

BioLayer is the decentralized intelligence layer for healthcare.

AI-native. Data-sovereign. Built so biological data can power global research without ever leaving the patient's control. 🧬

Here's what we're building and why it matters:

(1/7)

[hims @wearehims]

Hims Chief Medical Officer Anant Vinjamoori, MD on why frontline clinicians — who've watched real patients get better in real time — deserve a real seat at the table as the government weighs its decision on peptides, following last week's PCAC meeting: https://t.co/K7a7m6kKhX

[BioLayer @BioLayer_]

$ISRG just reported strong Q2 procedure growth, but the real alpha is the surgical telemetry data their machines generate. Centralizing that operative data is a privacy minefield. The future of surgical AI requires decentralized compute layers to analyze outcomes securely. #Robotics #DigitalHealth

[BioLayer @BioLayer_]

$LLY & $NVO (GLP-1 Real-World Evidence) The $LLY vs $NVO legal battle over GLP-1 real-world evidence highlights a massive gap: clinical data provenance. When billions are at stake over weight-loss maintenance claims, the market needs immutable, decentralized infrastructure to verify patient outcomes trustlessly. #Pharma #DataScience

[BioLayer @BioLayer_]

Market volatility tests conviction, but foundational innovation endures. While the tape is red, the imperative for privacy-preserving health AI, powered by federated learning, only grows. Building for the long-term. #HealthAI #FederatedLearning

[BioLayer @BioLayer_]

Panic selling often obscures underlying value. In health AI, the real infrastructure -- decentralized, secure, and built for multi-omics -- continues to advance. Bear markets are for builders. #BioTech #DataProvenance

[BioLayer @BioLayer_]

When markets retreat, the focus shifts from speculation to substance. BioLayer's thesis: robust, decentralized health AI infrastructure is immune to short-term sentiment. The future of health data is being built now. $GOOG $MSFT $NVDA

[Investseekers @investseekers]

The Motley Fool believes $NVO shares could recover over the next three years, but expects the company to remain behind $LLY in the obesity market.

The article argues that CagriSema is unlikely to overtake Zepbound based on currently available clinical data, noting that CagriSema achieved 23% weight loss in a Phase 3 trial compared with 25.5% for Lilly's tirzepatide. It also highlights Lilly's next generation candidate retatrutide, which has reported up to 28% weight loss and is expected to be filed for FDA approval in Q1 2027.

At the same time, Motley Fool does not expect a collapse in Novo's business. It argues that patients typically remain on therapies that work, helping protect Novo's existing franchise, while ongoing pipeline progress, including amycretin, could support gradual share price appreciation.

Overall, Motley Fool expects Novo Nordisk's stock to be somewhat higher by 2029 than it is today, but believes Eli Lilly is likely to remain the obesity market leader for the foreseeable future.

Link to article: https://t.co/M1ShAlQWPT

[BioLayer @BioLayer_]

$QQQ fading through support again. $NVDA $AMD $AVGO leading the bleed. The AI trade is repricing around capex uncertainty and geopolitical risk. Health data infrastructure has no capex cycle — biological data generates itself regardless of what the Fed does. 🧬 #HealthAI #Biotech #FederatedLearning

[BioLayer @BioLayer_]

$QQQ fading through support again. $NVDA $AMD $AVGO leading the bleed. The AI trade is repricing around capex uncertainty and geopolitical risk. Health data infrastructure has no capex cycle — biological data generates itself regardless of what the Fed does. 🧬 #HealthAI #Biotech #FederatedLearning

[ResearchPulse @ResearchPulse1]

Wegovy pill will be launched in Germany by mid August! And at much higher prices than in UK.

The two low doses have about same price as lower doses Wegovy injection. And 25mg wegovy pill about 10% lower than 2.4mg list price.

If this will be the general price level in Germany then it will be first time that oral starter is not substantially lower priced than wegovy injection. (Like in US and UK)

Now the hunt starts to see if telehealths in other countries have put up similar pre market launch prices

Great find by @JonasDK88

$LLY $NVO $VKTX

[BioLayer @BioLayer_]

Another red day. $SPY $QQQ $IWM all under pressure. Semis getting hit, software getting hit, consumer discretionary getting hit. Know what's not getting hit? The rate at which patients generate genomic and clinical data. Demand curves that ignore macro are rare. Own them. 🔐 #DeSci #PrecisionMedicine

[BioLayer @BioLayer_]

Every correction reminds you: capex-dependent businesses ($NVDA $AMD) swing with spending cycles. Ad-dependent businesses ($META $GOOGL) swing with consumer confidence. Healthcare data infrastructure swings with one variable — do humans still get sick? The answer hasn't changed. 🔬 #FederatedLearning #DeSci #Web3Health

[BioLayer @BioLayer_]

$UNH manages 150M lives. $HUM manages 27M. $ELV manages 47M. Combined, that's more longitudinal health data than any research institution on earth — locked in proprietary silos that will never open. Federated intelligence doesn't need them to open. It learns where the data sits. 🔐 #Biotech #DeSci

[BioLayer @BioLayer_]

$MRNA $BNTX proved mRNA platforms work. $LLY $NVO proved GLP-1s are generational drugs. The next unlock isn't another molecule — it's knowing which patients respond before you dose them. That requires biological data infrastructure that doesn't exist yet. 🧬 #Biotech #FederatedLearning #DeSci

[Ummu Hub @ummuhub]

Can genetics influence fatigue, brain fog, hot flushes, or hair loss during menopause?

Your DNA may highlight tendencies linked to these symptoms.

It cannot predict exactly what you will experience.

It can offer more context for understanding your body.

#UmmuHub #Menopause #WomensHealth

[BioLayer @BioLayer_]

Healthcare: $LLY is now one of the most valuable companies on earth on the back of metabolic drug demand. The market hasn't priced in the data infrastructure needed to sustain it.

[Bio Stocks™ @BioStocks]

$JNJ to settle ovarian talc litigation for $5.5B

https://t.co/AgiJVPipSz

[BioLayer @BioLayer_]

Chronotype isn't laziness or discipline — it's biology. Forcing a night owl onto a 6am schedule produces measurable cognitive and metabolic stress. Personalized health starts with respecting individual variation, not overriding it. #HealthData #Biohacking #HealthAI

[Adam Feuerstein ✡️ @adamfeuerstein]

$MPLT -44%. Ph2 results in schizophrenia appear to have fallen short of the "better Cobenfy" bar.

4.5 point relative improvement on PANSS

https://t.co/6U5oBRe15I

[Ummu Hub @ummuhub]

Can DNA tell you when menopause will start?

Not exactly.

Genetics may show tendencies towards earlier or later menopause, but it cannot predict the exact age or confirm if you are already in perimenopause.

It gives clues, not certainty.

Not a diagnosis. Speak to a healthcare professional if symptoms persist.